Follow-Up Note Examples for Clozapine Treatment Phases
Below are three clinical documentation examples for a 28-year-old male with treatment-resistant schizophrenia on clozapine, demonstrating the titration, optimization, and consolidation phases as outlined in current guidelines 1.
Week 4 Follow-Up: Titration Phase
Date: [Week 4 of clozapine initiation]
Patient: 28-year-old male with treatment-resistant schizophrenia
Current Clozapine Dose: 200 mg/day (100 mg BID)
Subjective:
Patient reports improved sleep and decreased auditory hallucinations compared to baseline. Denies suicidal ideation. Reports mild daytime sedation and increased salivation at night. No dizziness with position changes. Bowel movement yesterday, no constipation concerns.
Objective:
- Vital signs: BP 118/76 (sitting), 112/72 (standing after 1 min); HR 88 bpm; Temp 98.2°F
- Weight: 82 kg (baseline 80 kg, +2 kg)
- ANC: 4,200/μL (baseline 5,100/μL) - within normal limits
- Mental status: Alert, cooperative, thought process more organized, residual paranoid ideation present but less intense
Assessment:
Treatment-resistant schizophrenia, Week 4 of clozapine titration. Tolerating gradual dose escalation well per FDA-approved titration schedule 2. No orthostatic hypotension, fever, or signs of myocarditis. ANC monitoring appropriate per REMS requirements 2. Partial symptom improvement noted; target therapeutic dose not yet reached.
Plan:
- Continue titration: Increase clozapine to 250 mg/day (125 mg BID) today, then to 300 mg/day (150 mg BID) in 3-4 days if tolerated, per guideline recommendation to reach 300-450 mg/day by end of Week 2 1, 2
- Monitoring: Weekly ANC per REMS protocol 2; assess vital signs at each visit for orthostatic hypotension and tachycardia 2
- Metabolic protection: Started metformin 500 mg daily to attenuate weight gain per guideline recommendation 1
- Adverse effect management: Advised on sleep hygiene for sedation; towel on pillow for hypersalivation
- Bowel regimen: Initiated docusate 100 mg BID + senna PRN to prevent constipation 2
- Next visit: Week 5 for continued titration assessment and ANC monitoring
- Target: Reach 300-450 mg/day by Week 6, then obtain plasma clozapine level to guide further dosing 1
Month 8 Follow-Up: Optimization Phase
Date: [Month 8 of clozapine treatment]
Patient: 28-year-old male with treatment-resistant schizophrenia
Current Clozapine Dose: 400 mg/day (200 mg BID)
Subjective:
Patient reports persistent low-grade auditory hallucinations (voices commenting 2-3 times daily) despite 12 weeks at current dose. Denies command hallucinations or suicidal ideation. Adherence confirmed by pill counts and pharmacy records. No missed doses. Tolerating medication well aside from mild sedation in morning.
Objective:
- Vital signs: BP 124/78; HR 92 bpm; Temp 98.6°F
- Weight: 87 kg (baseline 80 kg, +7 kg over 8 months)
- Clozapine plasma level (trough): 285 ng/mL (drawn 12 hours post-dose)
- ANC: 3,800/μL - stable
- Fasting glucose: 102 mg/dL; Lipid panel: Total cholesterol 215 mg/dL, LDL 135 mg/dL
- BPRS total score: 48 (baseline 61) - 21% reduction
- Mental status: Residual paranoid delusions and auditory hallucinations present; functional impairment persists
Assessment:
Treatment-resistant schizophrenia on clozapine, Month 8. Subtherapeutic clozapine plasma level at 285 ng/mL - below the guideline-recommended target of at least 350 ng/mL 1. Partial response with 21% BPRS reduction but persistent positive symptoms. No pseudoresistance identified (adherence confirmed, no interacting medications, no inflammatory conditions). Metabolic monitoring shows mild weight gain and borderline glucose elevation.
Plan:
- Dose optimization: Increase clozapine to 500 mg/day (250 mg BID) to achieve plasma level ≥350 ng/mL per guideline recommendation 1
- Therapeutic drug monitoring: Repeat clozapine level in 4 weeks after dose stabilization; target 350-550 ng/mL range 1
- Metabolic management: Increase metformin to 1000 mg daily (500 mg BID); reinforce dietary counseling and exercise recommendations
- Monitoring: Continue monthly ANC; monitor for seizure risk with dose escalation 2
- Reassessment timeline: If persistent significant positive symptoms after 12-week trial at therapeutic plasma concentration (≥350 ng/mL), consider further dose increase to achieve level up to 550 ng/mL 1
- Next visit: 4 weeks for clozapine level check and symptom reassessment
Year 3 Follow-Up: Consolidation Phase
Date: [Year 3 of clozapine treatment]
Patient: 28-year-old male with treatment-resistant schizophrenia
Current Clozapine Dose: 450 mg/day (225 mg BID) - stable for 24 months
Subjective:
Patient reports sustained symptom control with no hallucinations for past 18 months. Denies delusions, suicidal ideation, or mood symptoms. Working part-time (20 hours/week) at grocery store for past 6 months. Living independently with weekly family support. Adherent to all medications. No new concerns.
Objective:
- Vital signs: BP 128/82; HR 88 bpm; Temp 98.4°F
- Weight: 91 kg (stable for past 12 months)
- Clozapine plasma level (trough): 420 ng/mL - therapeutic and stable
- ANC: 4,100/μL - stable (now on quarterly monitoring per REMS)
- Fasting glucose: 96 mg/dL; HbA1c: 5.6%; Lipid panel: Total cholesterol 195 mg/dL, LDL 118 mg/dL
- BPRS total score: 28 (baseline 61) - 54% reduction, sustained
- CGI-S: 2 (borderline mentally ill)
- Mental status: Euthymic, no psychotic symptoms, insight improved, engaged in treatment
Assessment:
Treatment-resistant schizophrenia, Year 3 on clozapine with excellent sustained response and functional recovery. Therapeutic plasma level maintained. Metabolic parameters well-controlled on metformin. Patient meets criteria for continued maintenance treatment per APA guidelines 3. Functional improvement with part-time employment represents significant quality of life gain.
Plan:
- Maintenance: Continue clozapine 450 mg/day (225 mg BID) - do not reduce dose given excellent response and guideline recommendation to continue same medication that achieved symptom improvement 3
- Monitoring schedule:
- ANC: Quarterly per REMS protocol (patient now in maintenance phase) 2
- Clozapine level: Every 6 months to ensure stability
- Metabolic panel (glucose, lipids): Every 6 months
- Weight and vital signs: Every 3 months
- Metabolic management: Continue metformin 1000 mg daily; patient maintaining stable weight with diet and exercise
- Psychosocial support: Continue supported employment services per guideline recommendation 3; consider cognitive-behavioral therapy for residual negative symptoms if they emerge 3
- Long-term plan: Maintain current regimen indefinitely given treatment-resistant diagnosis and excellent response; discontinuation not recommended given high relapse risk in treatment-resistant schizophrenia 3
- Next visit: 3 months for routine monitoring
Key Documentation Principles Demonstrated:
- Titration phase (Week 4): Focus on gradual dose escalation per FDA label 2, monitoring for orthostatic hypotension and myocarditis, establishing metabolic protection with metformin 1, and preventing constipation
- Optimization phase (Month 8): Emphasis on therapeutic drug monitoring to achieve plasma level ≥350 ng/mL 1, excluding pseudoresistance, and systematic dose adjustment based on objective levels rather than arbitrary dosing
- Consolidation phase (Year 3): Documentation of sustained response, functional recovery, appropriate monitoring intervals, and commitment to long-term maintenance without dose reduction per guideline recommendations 3
Each note demonstrates the algorithmic approach recommended by current guidelines 1, 3 while documenting safety monitoring per FDA requirements 2.